Is V-in-V the Treatment of Choice in Cases of Failed Biological Prosthesis?

Courtesy of Dr. Carlos Fava.

The treatment of choice for failed biological aortic prostheses has always been redo surgery (RS), with mortality rates approximately higher than for the first surgery.

¿El V-in-V es el tratamiento de elección en el fallo de las bioprótesis?

Nowadays, we have the chance to conduct valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI); however, while different analyses report great benefit derived from it, we still have very little information comparing both strategies.

Researchers analyzed 214 patients who underwent ViV TAVI and 344 who underwent RS.

Populations were very different: patients who underwent ViV TAVI were older and had more comorbidities, with increased risk. Consequently, subjects were propensity matched on 27 variables, which yielded 131 comparable pairs.

The time from initial surgical aortic valve replacement to ViV was 11.3 years, while it was 8.6 years to RS.


Read also: Always in Favor of Primary Angioplasty, Even in the Pandemic Era.


After a 30-day follow-up, mortality was lower among subjects in the V-in-V group (absolute risk difference: -7.5%; 95% confidence interval -12.6% to -2.3%). Additionally, the rates of blood transfusion and permanent pacemaker implantation were lower, and so was the number of hospitalization days (7 vs. 14 days; p < 0.001).

After 5 years of follow-up, the rates of survival were better for subjects who underwent ViV (76.8% vs. 66.8%; hazard ratio: 0.55; 95% confidence interval: 0.30 to 0.99; p = 0.04). Furthermore, there were no differences as regards hospital readmissions, major adverse cardiac events (MACE), and stroke.

Conclusion

ViV TAVI was associated with lower early mortality, morbidity, and length of hospital stay, and with increased survival compared with RS. Perhaps, it should be the treatment of choice in cases of failed biological prosthesis.

Courtesy of Dr. Carlos Fava.

 

Original title: Transcatheter ViV Versus Redo Surgical AVR for the Management of Failed Biological Prosthesis Early and Late Outcomes in a Propensity-Matched Cohort.

Reference: Derrick Y. Tam et al. J Am Coll Cardiol Intv 2020;13:765-74


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...